<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03965065</url>
  </required_header>
  <id_info>
    <org_study_id>19/153-R_P</org_study_id>
    <nct_id>NCT03965065</nct_id>
  </id_info>
  <brief_title>Comparison of Sutureless Vs. Standard Biological Prostheses for Surgical Aortic Valve Replacement</brief_title>
  <acronym>COPERA</acronym>
  <official_title>Comparison of Sutureless Vs. Standard Biological Prostheses for Surgical Aortic Valve Replacement: a Randomised Multicenter Study (Madrid, Spain)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital San Carlos, Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital San Carlos, Madrid</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter randomised study which aims to compare sutureless Vs. standard bio- prostheses
      (1:1) among patients undergoing surgical aortic valve replacement in terms of:

        -  6 -month hemodynamic performance.

        -  6 month clinical outcomes including all cause mortality, stroke, myocardial infarction,
           valve reoperation and major/life threatening bleeding

        -  Cost effectiveness
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is aimed to compare clinical and hemodynamic performance of conventional sutured
      stented bio-prostheses among patients undergoing a surgical aortic valve replacement. The
      prostheses are not pre specified to be provided by a specific manufacturer, so that any bio
      prosthesis but transcatheter and scentless aortic valves can be implanted.

      The estimated sample size is 350 patients. They will be randomised 1:1 to any of the two arms
      of the study (standard Vs. sutureless prostheses). The randomisation will be stratified
      according to the need for a concomitant coronary artery bypass grafting procedure.

      Six hospitals in Madrid (Spain) will take part in the study. The period of recruitment will
      start as soon as June 2019 and is supposed to finish by June 2020 or earlier.

      The main outcomes of the study will be measured 6 months after the aortic valve implantation
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2019</start_date>
  <completion_date type="Anticipated">May 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Block randomisation 1:1 of conventional Vs sutureless aortic bioprostheses.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in mid term trans prosthetic gradients</measure>
    <time_frame>6 month</time_frame>
    <description>The differences in mid term trans prosthetic gradients measured by trans thoracic echocardiogram 6 months after the procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival from Combined major adverse cardiovascular event</measure>
    <time_frame>6 month</time_frame>
    <description>Comparison of survival free from a combined event including: all cause mortality, major stroke (mRS&gt;1), Myocardial Infarction (according to VARC-II criteria), Valve re operation of any case, major or life-threatening bleeding (VARC 2 definition)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in quality if life according to the KCCQ12 questionnaire</measure>
    <time_frame>6 month</time_frame>
    <description>Quality of life will be compared between the two groups using the Kansas City Cardiomyopathy Questionnaire (KCCQ12). The response options of the items are Likert scales of 1 to 5, 6 or 7 points and the score has a theoretical range of 0 to 100, with 100 being the best</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Heart Valve Prosthesis</condition>
  <condition>Aortic Stenosis</condition>
  <condition>Hemodynamics</condition>
  <arm_group>
    <arm_group_label>Sutureless Aortic Valve Prosthesis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving sutureless aortic valve prostheses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Aortic Valve Prosthesis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving conventional biological aortic prostheses</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sutureless aortic bioprosthesis</intervention_name>
    <description>Patients will receive a sutureless aortic bioprosthesis</description>
    <arm_group_label>Sutureless Aortic Valve Prosthesis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional stented sutured aortic prosthesis</intervention_name>
    <description>Patients will receive a stented sutured aortic prosthesis</description>
    <arm_group_label>Conventional Aortic Valve Prosthesis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18

          -  Pure aortic stenosis or combined aortic stenosis/regurgitation

          -  Aortic annulus &gt;18 mm and &lt; 27 mm

        Exclusion Criteria:

          -  Pregnancy

          -  Willing to receive some other prosthesis

          -  Concomitant surgery of the ascending aorta or left ventricle outflow tract

          -  Endocarditis

          -  Emergency

          -  Some other concomitant procedure

          -  Participation in any other study

          -  Previous surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Carnero, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinico San Carlos. Madrid. Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuel Carnero, MD, PhD</last_name>
    <phone>+34913303000</phone>
    <phone_ext>3691</phone_ext>
    <email>manuel.carnero@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Cl√≠nico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Carnero, MD, PhD</last_name>
      <phone>+34913303000</phone>
      <phone_ext>3691</phone_ext>
      <email>manuel.carnero@salud.madrid.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital San Carlos, Madrid</investigator_affiliation>
    <investigator_full_name>Manuel Carnero Alcazar</investigator_full_name>
    <investigator_title>Adult Cardiac Surgeon, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Aortic Stenosis</keyword>
  <keyword>Heart Valve Prosthesis</keyword>
  <keyword>Hemodynamics</keyword>
  <keyword>Sutureless</keyword>
  <keyword>Standard aortic valve prosthesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

